Status: Not yet recruiting
A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects with HPV Positive HNSCC.
BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18. This clinical trial for BVAC-E6E7 consists of two phases: PhaseⅠfocuses on safety and tolerance to determine the maximum tolerated dose (MTD), while Phase Ⅱ evaluates its efficacy.
Participants needed: 37
Trial details
Phase: Phase 1, Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: Cellid Co., Ltd.Updated: Jan 29, 2025
Eligibility criteria
Adult male and female aged 19 and above at the time of acquisition informed cons... [+9]
Patients with a history of malignant tumor, excluding Head and neck squamous cel... [+31]